Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada [3] - Phathom markets vonoprazan in the U.S. as VOQUEZNA® for various gastrointestinal conditions, including heartburn associated with Non-Erosive GERD and H. pylori infection treatment [3] Upcoming Events - Members of Phathom's management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 12, 2026 [1] - The conference will take place from February 11-12, 2026, in New York, NY, and will include one-on-one meetings [2] - A live webcast and archived recordings of the event will be available on Phathom's website for 90 days following the meeting [2]